CBChristopher Banfield

Christopher Banfield

*This is an algorithmically generated author record based on publicly available information.

Christopher Banfield has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Early exposure-response modeling of an interferon-beta monoclonal antibody (dazukibart) in adults with dermatomyositis

    by John P. Prybylski, Jing ‘dAisy’ Zhu, Christopher Banfield, Arnab Mukherjee, Vivek Purohit

    Dermatomyositis (DM) is a rare and debilitating inflammatory disease associated with muscle weakness and skin manifestations. As with all rare diseases, clinical trials in DM are challenging due to the small number of patients available for study, and DM patients may even present with skin- or muscle-predominant disease. A Phase 2 study of an anti-interferon-beta monoclonal antibody (dazukibart) in DM was recently completed. Most trial data were collected in skin-predominant DM patients, measuring the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI); the Total Improvement Score (TIS) was only measured in a small subset of muscle-predominant DM patients. Because TIS is a more holistic endpoint, planning for further dazukibart development depended on a robust understanding of TIS response. This analysis aimed to develop an exposure-response model for dazukibart in DM patients. The model was intended to describe the timecourses of all relevant clinical responses, including CDASI and TIS, using the available data to collectively inform the exposure-response relationships. The model provided evidence for a TIS response in DM patients treated with dazukibart that was consistent with the observed data and supportive of further development. The model used here could be applied directly to model-based meta-analysis of other DM trials, and the general approach can be used in rare diseases with multiple endpoints. Trial registration numbers: NCT03181893, NCT02766621.

  • Open Access

    Population pharmacokinetic modeling of oral brepocitinib in healthy volunteers and patients with immuno‐inflammatory diseases

    by Farzaneh Maleki, Elias Clark, Christopher Banfield, Wonkyung Byon, Timothy Nicholas

    The objective of this population pharmacokinetic (PK) analysis was to characterize the concentration–time profile of brepocitinib plasma concentration after single‐ and multiple‐oral administration in healthy volunteers (HVs) and patients with immuno‐inflammatory diseases. Blood samples from phase I HV and phase II clinical studies of patients with alopecia areata, psoriasis, psoriatic arthritis, ulcerative colitis (UC), vitiligo, and hidradenitis suppurativa were analyzed using a nonlinear mixed‐effects modeling approach. Effects of patients' characteristics on brepocitinib exposure were investigated. Overall, 8552 brepocitinib plasma concentrations from 775 individuals were included in the analysis. The PKs of brepocitinib were adequately described by a two‐compartment model with first‐order absorption and a lag time for tablet formulation, dose‐dependent bioavailability, and Box–Cox transformed interindividual variabilities on apparent clearance (CL/F) and apparent central volume of distribution (Vc/F). For a typical 70‐kg non‐Asian female patient with baseline aspartate aminotransferase of 22 unit/liter, CL/F and Vc/F estimates were 17.5 L/h and 88.5 L, respectively. Asians had a higher exposure (independent of body weight), caused by a 10% lower CL/F when compared to other individuals. Independent of baseline body weight, the male population showed 13% higher Vc/F compared to the female population. Patients with UC were predicted to have 46% slower absorption rate compared to other individuals. The PKs of brepocitinib were well‐characterized by a two‐compartment model with first‐order absorption and dose‐dependent bioavailability. Several covariates, such as race and sex, were identified to have statistically significant, but not clinically meaningful, effects on the estimated PK parameters.


  • Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor PF-06700841 Reveal Reduction of Skin Inflammation in Plaque Psoriasis

    by Karen M. Page, Mayte Suarez-Farinas, Maria Suprun, Weidong Zhang, Sandra Garcet, Judilyn Fuentes-Duculan, Xuan Li, Matthew Scaramozza, Elizabeth Kieras, Christopher Banfield, et al.


  • Desloratadine Demonstrates Dose Proportionality in Healthy Adults After Single Doses

    by Samir Gupta, Christopher Banfield, Melton Affrime, Aliceann Marco, Mitchell Cayen, Jerry Herron, Desmond Padhi

    Objective: To evaluate the dose proportionality and linearity and pharmacokinetic profile of desloratadine after single oral doses over the range of 5 to 20mg. Design: Single centre, randomised, open-label, 4-way crossover study in which healthy adults received single doses of desloratadine (5, 7.5, 10 and 20mg) in 4 different treatment periods. Desloratadine was administered each morning after a 10-hour fast. A washout period of at least 14 days separated each dose. Plasma concentrations were measured prior to each treatment and over the 168 hours after drug administration to determine the area under the plasma concentration-time curve (AUC) and maximum observed plasma concentration (Cmax). Participants: 20 healthy male volunteers (3 White, 17 Black) ranging in age from 19 to 45 (mean 37) years and weighing 54 to 91 (mean 75) kg were enrolled and completed this study. Main outcome measures: The primary parameter to assess dose proportionality and linearity was AUC from time zero to final concentration time point (AUCs). Results: The Cmax for all doses was observed approximately 4 hours after administration, revealing no dose-related differences in absorption rate. The half-life (t1/2) ranged from 21.2 to 24.1 hours. Cmax and AUCs increased in a doseproportional manner over a dose range of 5 to 20mg. Although the recommended clinical dose is 5mg, doses up to 20mg were well tolerated. Conclusion: In this study, single doses of desloratadine as high as 4 times the recommended clinical dose of 5mg were well tolerated. The Cmax and AUCs for doses of 5 to 20mg increased in a dose-proportional manner.


  • Open Access

    Single‐dose pharmacokinetics of felbamate in patients with renal dysfunction

    by P. Glue, W. Sulowicz, R. Colucci, C. Banfield, S. Pai, C. Lin, M. B. Affrime

    Aims The purpose of this study was to evaluate the effects of renal impairment on the single‐dose pharmacokinetics of the antiepileptic felbamate. Methods Twelve subjects with three levels of renal dysfunction (creatinine clearance >30–80, >10–30 or 5–10 m min−1 ) and four controls with normal renal function (creatinine clearance >80 ml min−1 were studied). Plasma and urine samples were obtained for 144 h following administration of a single 1200 mg dose. Results Compared with controls, apparent total body clearance, renal clearance and urinary excretion of felbamate were decreased, and half‐life, Cmax and AUC values were increased in subjects with renal dysfunction. The magnitude of these changes was associated with the degree of renal dysfunction. Nonrenal clearance and apparent volume of distribution values were also lower in renal dysfunction subjects, but there was no association between the extent of these changes and degree of renal dysfunction. Renal clearance of felbamate accounted for approximately 30% of apparent total body clearance in the control group and from 9–22% in the renal failure patients. Renal clearance of felbamate was significantly correlated with creatinine clearance (r2=0.75; PConclusions These data suggest that initial dosage and titration of felbamate may require adjustment in patients with renal dysfunction.


  • EFFECT OF FELBAMATE ON THE PHARMACOKINETICS OF CLONAZEPAM

    by R. Colucci, P. Glue, C. Banfield, P. Reidenberg, J. Meehan, E. Radwanski, C. Korduba, C. Lin, P. Dogterom, T. Ebels, et al.

    To assess the possible interaction between clonazepam and felbamate, a double-blind, randomized, placebo-controlled, two-way crossover study was conducted in 18 healthy male volunteers. Volunteers were administered clonazepam (1 mg q12h) and felbamate (1200 mg q12h) or matching placebo for 10 days during each period of the crossover. Following morning dosing on day 10, blood samples were obtained over 12 h for the determination of clonazepam and the metabolites 7-amino-clonazepam and 7-acetamido-clonazepam. Felbamate increased clonazepam's Cmax and AUC0–12h by 17% and 14%, respectively (p<0.01). The 90% confidence intervals following log-transformation for each of these pharmacokinetic parameters were within the generally accepted interval (80–125%) for bioequivalence. Felbamate had no significant effect on the pharmacokinetics of 7-amino-clonazepam, whereas 7-acetamido-clonazepam concentrations were below the limit of quantification in all but one subject. Adverse events were mainly central nervous system in nature, with a greater incidence reported during coadministration with felbamate compared with placebo. Overall, felbamate appears to have no clinically relevant effects on the pharmacokinetics of clonazepam.